Literature DB >> 23680813

Screening miRNA and their target genes related to tetralogy of Fallot with microarray.

Xian-min Wang1, Kui Zhang2, Yan Li1, Kun Shi1, Yi-ling Liu1, Yan-feng Yang1, Yu Fang1, Meng Mao1.   

Abstract

Our aim is to screen miRNAs and genes related to tetralogy of Fallot and construct a co-expression network based on integrating miRNA and gene microarrays. We downloaded the gene expression profile GSE35490 (miRNA) and GSE35776 (mRNA) of tetralogy of Fallot from the Gene Expression Omnibus database, which includes eight normal and 15 disease samples from infants, and screened differentially expressed miRNAs and genes between normal and disease samples (cut-off: p < 0.05; FDR < 0.05; and log FC > 2 or log FC < -2); in addition, we downloaded human miRNA and their targets, which were collected in the miRNA targets prediction database TargetScan, and selected ones that also appeared in our differentially expressed miRNAs and their predicted targets (score >0.9) and then made a relationship of diff_miRNAs and diff_genes of our results. Finally, we uploaded all the diff_target genes into String, constructed a co-expression network regulated by diff_miRNAs, and performed functional analysis with the software DAVID. Comparing normal and disease lesion tissue, we got 32 and 875 differentially expressed miRNAs and genes, respectively, and found hsa-miR-124 with 34 diff_target genes and hsa-miR-138 with two diff_target genes. Then we constructed a co-expression network that contains 231 pairs of genes. Genes in the network were enriched into 14 function clusters, and the most significant one is protein localisation. We screened the tetralogy of Fallot-related hsa-miR-124 and hsa-miR-138 with their direct and indirect differentially expressed target genes, and found that protein localisation is the significant cause affecting tetralogy of Fallot. Our approach may provide the groundwork for a new therapy approach to treating tetralogy of Fallot.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23680813     DOI: 10.1017/S104795111300053X

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  5 in total

Review 1.  Cellular and molecular basis of RV hypertrophy in congenital heart disease.

Authors:  D Iacobazzi; M-S Suleiman; M Ghorbel; S J George; M Caputo; R M Tulloh
Journal:  Heart       Date:  2015-10-29       Impact factor: 5.994

2.  Analysis of circulating microRNAs in patients with repaired Tetralogy of Fallot with and without heart failure.

Authors:  Masood Abu-Halima; Eckart Meese; Andreas Keller; Hashim Abdul-Khaliq; Tanja Rädle-Hurst
Journal:  J Transl Med       Date:  2017-07-10       Impact factor: 5.531

3.  Aberrant expression of miR-29b-3p influences heart development and cardiomyocyte proliferation by targeting NOTCH2.

Authors:  Qian Yang; Fang Wu; Yaping Mi; Feng Wang; Ke Cai; Xiaoshan Yang; Ranran Zhang; Lian Liu; Yawen Zhang; Youhua Wang; Xu Wang; Mingqing Xu; Yonghao Gui; Qiang Li
Journal:  Cell Prolif       Date:  2020-02-20       Impact factor: 6.831

4.  RNA expression profiles and regulatory networks in human right ventricular hypertrophy due to high pressure load.

Authors:  Philippe Chouvarine; Joachim Photiadis; Robert Cesnjevar; Jens Scheewe; Ulrike M M Bauer; Thomas Pickardt; Hans-Heiner Kramer; Sven Dittrich; Felix Berger; Georg Hansmann
Journal:  iScience       Date:  2021-02-27

Review 5.  The Role of Epigenetics in Congenital Heart Disease.

Authors:  Tingsen Benson Lim; Sik Yin Roger Foo; Ching Kit Chen
Journal:  Genes (Basel)       Date:  2021-03-09       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.